Compare Ascendis Pharma A/S (ASND) vs Nucor Corporation (NUE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Nucor Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Nucor Corporation trades at $225.91 (market cap $51.78B). The key difference: Nucor Corporation is far larger — about 2.9× Ascendis Pharma A/S's market cap, and Nucor Corporation pays a 0.99% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NUE | |
|---|---|---|
Market Cap | $17.74B | $51.78B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $266.35 |
52-Week Low | $163.32 | $131.78 |
Enterprise Value | $18.11B | $56.42B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Nucor (NUE) trades at $227.37, up 2.29% today, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 22.56 and net margin of 6.82%, while revenue has declined from $41.5B in 2022 to $32.5B in 2025. Recent news highlights a joint venture for AI power infrastructure and a 53-year dividend growth streak, supporting shareholder returns amid steel price volatility.
Outlook remains cautiously optimistic with a consensus price target of $262.89 (15.6% upside), driven by expansion projects and pricing strength. Risks include cyclical demand weakness and declining operating cash flow, but analyst sentiment is 59% buy-rated. The stock offers value through dividends and buybacks, though investors should monitor steel market dynamics and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
